Onglyza (generic name: Saxagliptin) helps type 2 diabetes patients regulate their blood sugar. Along with Kombiglyze XR, it belongs to a drug class known as DPP-4 inhibitors. Recent studies found Onglyza patients are more likely to be hospitalized for heart failure than type 2 diabetics taking other blood sugar-lowering medications. After receiving hundreds of adverse event reports involving cardiac arrest, congestive heart failure, or other life-threatening cardiovascular events, the FDA issued a drug safety warning in 2014. Now, Onglyza patients suffering from cardiovascular damage are suing the drug’s manufacturer for not warning them about this potential side effect.
If you or someone you love suffered heart problems while taking saxagliptin, fill out your free claim review today to see if you may qualify for a cash settlement. We’ll connect you with an experienced attorney for a free legal consultation in your area to review your case as well as compensation options.
It seems we can’t find what you’re looking for. Perhaps searching can help. Type some text and hit enter.